Intelligence · Clinical Development
Pipeline search results
Programs matching “brentuximab vedotin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 17 pipeline programs matching "brentuximab vedotin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Brentuximab Vedotin
Takeda
Primary Cutaneous Anaplastic Large Cell Lymphoma
1 trial -
Brentuximab Vedotin for Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Classical Hodgkin Lymphoma
1 trial -
Brentuximab vedotin
Takeda
Diffuse Large B-cell-lymphoma
1 trial -
Brentuximab vedotin
Pfizer
Diffuse Large B-cell Lymphoma
1 trial -
brentuximab vedotin
Takeda
Hodgkin Lymphoma
3 trials -
ADCETRIS 50 mg powder for concentrate for solution for infusion
Takeda
Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.
1 trial -
Brentuximab Vedotin
United Therapeutics Europe Ltd
Ann Arbor Stage IB Hodgkin Lymphoma
1 trial -
Brentuximab Vedotin
Takeda
Enteropathy Associated T-cell Lymphoma
1 trial -
Brentuximab Vedotin
Takeda
Hodgkin Disease
2 trials -
Brentuximab Vedotin in Combination with Tislelizumab
Takeda
NK/T Cell Lymphoma Nos
1 trial -
Brentuximab vedotin
Takeda
Relapsed or Refractory Hodgkin Lymphoma
1 trial -
Brentuximab Vedotin
Takeda
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
1 trial -
TGR-1202 + brentuximab vedotin
TG THERAPEUTICS, INC.
Hodgkin's Lymphoma
1 trial -
Brentuximab vedotin
Takeda
Lymphoma
2 trials -
Brentuximab vedotin
Takeda
T-Cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.